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Immunoglobulin (Ig) A is critical for protective immune responses at mucosal surfaces. In this issue of
Immunity, Tezuka et al. (2011) identify an important relay between stromal cells and plasmacytoid dendritic
cells that regulates IgA production by murine B cells.B cells have the capacity to undergo
class switch recombination (CSR) allow-
ing them to secrete multiple classes of
immunoglobulin (Ig) isotypes. This repre-
sents one mechanism of Ig diversification
whereby B cells alter the effector function
of their antibody (Ab) products without
modifying Ag specificity. Each of these
Ig classes have preferential roles in
immune responses depending on their
site of generation and nature of the anti-
genic stimulus. Thus, IgG is produced
systemically and comprises most of the
Ig in serum and extravascular compart-
ments where it predominantly functions
in antiviral and antibacterial immunity. In
contrast, IgE exists at extremely low con-
centrations in serum but is produced in
response to parasitic infections, as well
as allergens, whereas IgA is secreted
predominantly in mucosal tissues and
represents the majority of Ig in these sites
(Cerutti et al., 2010).
CSR can occur via T cell-dependent
(TD) and T cell-independent (TI) mecha-
nisms. TD CSR typically requires the
integration of signals provided by cognate
CD4+ T cells in the form of CD40 ligand
(CD40L) interacting with CD40 on B cells
in a cell contact-dependent manner and
a soluble cytokine. Whereas CD40L
primes B cells to switch to all Ig isotypes,
TGF-b is considered to be the obligatory
cytokine required for the majority of IgA
produced by human and murine B cells
(Cerutti et al., 2010; Tangye et al., 2006).
The TI pathway for CSR to IgA involves
signaling through Toll-like receptors
(TLRs) as well as the cytokines BAFF
and APRIL, which are produced by many
cell types including hematopoietic and
nonhematopoietic cells (Cerutti et al.,
2010; Tangye et al., 2006). However,
BAFF and APRIL can also induce CSR in
the presence of appropriate T cell-derived144 Immunity 34, February 25, 2011 ª2011 Ecytokines—TGF-b for IgA—albeit in a
CD40L-independent manner (Cerutti
et al., 2010). Thus, these cytokines can
contribute to both TD and TI CSR. Inter-
estingly, there appears to be a ‘‘division
of labor’’ between the function of IgA
produced by TD and TI pathways
whereby high-affinity IgA generated
during TD responses is important for
neutralization and clearance of patho-
genic microorganisms, whereas low-
affinity IgA arising from TI responses
maintains commensal bacteria-depen-
dent homeostasis within the gut (Cerutti
et al., 2010). An issue that has not been
completely resolved, however, is the
contribution of dendritic cell (DC) subsets
to IgA production. This is the subject of
the paper by Tezuka et al. (2011) in this
issue of Immunity.
The partitioning of IgA responses to
mucosal associated lymphoid tissues
(MALT) appears inconsistent with the sys-
temic production of BAFF, APRIL, CD40L,
and TGF-b by numerous cell types pre-
sent throughout all lymphoid tissues.
Consequently, several studies have ad-
dressed the questions of (1) why B cells
preferentially switch to IgA in MALT and
(2) why IgA+ B cells are retained at these
sites. The answer to both of these ques-
tions appears to depend on the function
of (DCs) located in mucosal tissues. First,
DCs from Peyer’s patches (PP) were
found to be distinct from those in spleen
or lymph nodes (LN) inasmuch that PP,
but not splenic or LN, DCs were potent
inducers of large quantities of IgA by B
cells (Massacand et al., 2008; Mora
et al., 2006; Sato et al., 2003). One of the
mediators responsible for this effect of
MALT-derived DCs is retinoic acid (RA)
(Massacand et al., 2008; Mora et al.,
2006; Uematsu et al., 2008). Indeed,
exogenous RA converts splenic DCs intolsevier Inc.potent helpers for IgA secretion by cocul-
tured human and murine B cells (Mora
et al., 2006; Uematsu et al., 2008).
Second, the tropism of IgA+ cells for
MALT reflects the conditioning of these
cells by DCs during mucosal responses.
Specifically, RA imprints upon IgA-
secreting B cells expression of CCR9
and a4b7 (Mora et al., 2006), character-
istic gut-homing receptors that attract
and/or retain cells in the MALT by
rendering them responsive to the chemo-
kine CCL28 and the adhesion molecule
MadCAM-1, both of which are highly
expressed in mucosal tissues.
Because many subsets of conventional
DCs exist, attempts have been made to
identify the population of MALT DCs
responsible for inducing IgA secretion.
Both a CD11clo TNF+iNOS-producing
(Tip) (Tezuka et al., 2007) and a
CD11chiCD11bhi (Uematsu et al., 2008)
DC subset have been attributed to have
the ability of regulating IgA production in
MALT (Figure 1). Despite these insights,
the mechanisms underlying DC-mediated
IgA secretion are not only complex, but
incompletely resolved. For instance, the
effects of the Tip-DC subset on TD IgA
CSR relied on induction of TGF-bRIII on
B cells by nitric oxide (NO), whereas they
regulated TI IgA secretion in a BAFF-
and APRIL-dependent manner that re-
quired endogenous iNOS expression.
Furthermore, iNOS expression by Tip-
DCs required MyD88 signaling down-
stream of TLR2, TLR4, and/or TLR9
(Figure1, top;Tezukaetal., 2007).Theacti-
vation requirements of CD11chiCD11bhi
DCs differed from Tip-DCs. Thus, RA
production by CD11chiCD11bhi DCs was
necessary to induce TI IgA secretion
(Massacand et al., 2008; Uematsu et al.,
2008), and this depended exclusively on
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Figure 1. Distinct Mechanisms Underlie the Ability of Different Subsets of Conventional and
Plasmacytoid DCs to Regulated IgA Secretion in Mucosal Tissues
CD11clo TNF and iNOS-producing (Tip) cDCs induce TI and TD IgA production via the secretion of BAFF
and APRIL, and nitric oxide (NO), respectively. NO induces expression of TGF-bRIII on B cells, which
presumably allows them to respond to CD4+ T cell-derived TGF-b. Production of both BAFF, APRIL,
and NO requires TLR stimulation of the cDCs. In contrast, CD11chiCD11bhi cDCs induce IgA secretion
by inducing RA in a TLR5-dependent manner. pDCs, however, express membrane (memb) BAFF
and APRIL in response to type I IFNs released by stromal cells after exposure to commensal bacteria.
IFN-primed pDCs migrate to B cell areas to induce TI IgA production.
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necessary for IgA induced by Tip-DCs
(Figure 1, bottom; Tezuka et al., 2007).
Lastly, IL-6 has been found to be either
required (Sato et al., 2003) or dispens-
able (Mora et al., 2006) for IgA secre-
tion induced by MALT DCs. Thus,
mucosal DC subsets appear to be
capable of inducing IgA secretion by
several mechanisms.
Tezuka et al. (2011) extended these
studies by dissecting the role of plasma-
cytoid DCs (pDCs) in IgA production. A
striking observation was that pDCs
derived from MALT, including PP and
mesenteric LNs (MLN), were more effi-
cient at inducing TI IgA secretion by Bcells than were conventional DCs (cDC)
isolated from these same sites, or even
pDCs from peripheral LNs (PLN). Analysis
of both cDCs and pDCs revealed that
pDCs from MLN or PP expressed greater
amounts of BAFF and APRIL mRNA and
produced more IL-6 than corresponding
cDCs or PLN pDCs. Consistent with these
findings, IgA secretion by B cells cultured
with MALT pDCs was reduced dramati-
cally by neutralizing BAFF and APRIL
and less so by blocking IL-6. Further
examination of interactions between
pDCs and B cells demonstrated that
membrane-bound BAFF and/or APRIL
were necessary for pDCs to induce IgA
production. Indeed, BAFF and APRILImmunity 34,were present on the surface of a small
but detectable proportion of pDCs but
not cDCs. By contrast, no role was found
for TGF-b or RA in pDC-induced IgA
production (Tezuka et al., 2011).
The final question addressed what the
factors were that induced expression of
BAFF and APRIL on pDCs. Type I IFNs
were a likely candidate because they up-
regulate BAFF in myeloid cells (Cerutti
et al., 2010; Tangye et al., 2006) and
enhance Ab responses (Jego et al.,
2003). When pDCs were obtained from
MLNs of Ifnar1-deficient mice, their
capacity to induce IgA was impaired;
thiswas a direct consequence of a paucity
of BAFF and APRIL in these cells (Tezuka
et al., 2011). Although pDCs themselves
produce vast quantities of type I IFNs in
response to viral stimulation (Jego et al.,
2003), the IFN-producing cells respon-
sible for inducing BAFF and APRIL in
MALT pDCs were of stromal origin.
Notably, the degree of type I IFN expres-
sion by stromal cells in PP exceeded
that of those in the spleen (Tezuka et al.,
2011). This provides a mechanistic basis
for the improved efficacy of MALT-
derived pDCs in inducing IgA secretion
over pDCs from PLN.
Taken together, these findings suggest
that under steady-state noninflammatory
conditions, interactions between stromal
cells and pDCs result in BAFF and
APRIL production by pDCs in a type I
IFN-dependent manner. These cytokines
then act on B cells to induce CSR to,
and subsequent secretion of, IgA (Fig-
ure 1, bottom). Expression of type I IFNs
by stromal cells in PP also required TLR
signaling, presumably after exposure to
commensal microbes. Collectively, an
ongoing dialog between these distinct
cell types substantially contributes to TI
IgA production, which is important for
not only mucosal immunity but also gut
homeostasis. Although stromal cells
clustered with pDCs and pDCs clustered
with B cells, there was little evidence of
interactions occurring simultaneously
between these three cell types. Thus, a
relay needs to be established whereby
IFN-primed BAFF- and APRIL-producing
pDCs relocate from their position adja-
cent to stromal cells to one in close prox-
imity with B cells (Figure 1). Although the
cues that guide migration of pDCs to B
cell follicles are unknown, TLR-stimulated
follicular DCs in PP were recently shownFebruary 25, 2011 ª2011 Elsevier Inc. 145
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Previewsto produce BAFF, APRIL, and CXCL13 as
well as molecules that enable TGF-b
synthesis that together control IgA secre-
tion in MALT (Suzuki et al., 2010). It would
therefore be interesting to determine
whether follicular DCs are also involved
in this relay by recruiting activated
pDCs to B cell follicles to regulate IgA
production.
By demonstrating a major role for
MALT-resident pDCs, rather than cDCs,
in regulating TI IgA responses under
steady-state conditions, these findings
(Tezuka et al., 2011) add another layer
of complexity to the regulation of mu-
cosal IgA responses. In light of other
studies (Jego et al., 2003; Massacand
et al., 2008; Mora et al., 2006; Sato et al.,
2003; Suzuki et al., 2010; Tezuka et al.,
2007; Uematsu et al., 2008), it is clear
that induction of IgA by DCs differentially
depends on TGF-b, IL-6, RA, BAFF, and
APRIL, with the requirement for each of
these factors reflecting the nature of the
DC subset, the inflammatory or quiescent
milieu, the availability of T cell help, and
the specific location within the MALT
(Figure 1). These findings also raise
several interesting questions. First, it
remains unclear why IgA responses in
PP were predominantly TD whereas
those in the MLN were TI despite the146 Immunity 34, February 25, 2011 ª2011 Efact that pDCs and stromal cells isolated
from these sites appeared to be function-
ally similar with respect to expression of
elevated amounts of BAFF and APRIL
and type I IFNs, respectively, compared
to corresponding cells in non-MALT sites
(i.e., spleen, PLN). Second, it is unknown
whether BAFF, APRIL, or BAFF-APRIL
heterodimers or a combination of these
molecules is the key mediator of pDC-
induced IgA secretion. And lastly, the
receptor expressed on B cells that
delivers the BAFF and APRIL signal for
CSR to IgA in this setting remains to be
identified. Although TACI has been impli-
cated in IgA production in vitro (Cerutti
et al., 2010; Tangye et al., 2006), it will
be important to establish whether this
also occurs within MALT and whether
an impairment in this pathway contrib-
utes to the Ig deficiency in humans with
mutations in TNFRSF13B (encoding
TACI). Although this study by Tezuka
et al. (2011) has shed substantial light
on the dynamic control of IgA production,
answers to these questions will pro-
vide a greater understanding of the
biology of IgA-mediated immunity during
TD and TI responses and potentially
reveal strategies for improving such
responses in healthy and immunodefi-
cient individuals.lsevier Inc.REFERENCES
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Most successful vaccines elicit antibodies that protect against infection. In this issue of Immunity, Bomsel
et al. (2011) show in the rhesus macaque model that vaccine-induced mucosal antibodies, rather than circu-
lating neutralizing antibodies, may be critical components for protective immunity against HIV-1.Antibodies patrolling the mucosal epithe-
lium can play a crucial role in blocking
HIV-1entryand infectionafter sexual expo-
sure. Bomsel et al. (2011), in this issue of
Immunity, report that an HIV-1 gp41 enve-
lope vaccine elicits mucosal antibodies in
rhesusmacaques thatmay protect againstsimian-human chimeric immunodeficiency
virus (SHIV) infection after repeated intra-
vaginal low-dose exposures (Bomsel
et al., 2011). Protected animals mounted
vaginal IgA antibodies, which blocked
HIV-1 transcytosis, and IgG antibodies,
which mediated antibody-dependentcellular cytotoxicity (ADCC). However, the
animals lacked serum neutralizing anti-
bodies. These findings highlight the contri-
bution of diverse effector activities of anti-
bodies in defending against HIV-1 at the
portal of entry and raise the question of
whether circulating, broadly reactive
